<DOC>
	<DOCNO>NCT01580202</DOCNO>
	<brief_summary>Patients chronic hepatitis B undergoing anticancer chemotherapy risk HBV reactivation hepatitis flare . Lamivudine ( LAM ) prophylaxis recommend circumstance accord practice guideline despite limited evidence . However , failure LAM prophylaxis include virologic breakthrough withdrawal hepatitis occur occasionally , may lead liver-related morbidity mortality well premature interruption delay chemotherapy . Given relatively frequent drug resistance LAM , study proper prophylactic antiviral regimen warrant . The present multicenter , prospective , randomize study aim compare effect entecavir ( ETV ) versus LAM prevention HBV reactivation HBsAg-positive patient hematologic oncologic malignancy undergo cytotoxic chemotherapy .</brief_summary>
	<brief_title>Comparison Prophylactic Antiviral Efficacy Patients Undergoing Chemotherapy : Entecavir Versus Lamivudine</brief_title>
	<detailed_description>Chronic hepatitis B virus ( HBV ) carrier undergo anticancer chemotherapy risk HBV reactivation hepatitis flare , lamivudine ( LAM ) prophylaxis recommend accord practice guideline despite limited evidence . However , failure LAM prophylaxis define virologic breakthrough LAM therapy withdrawal hepatitis discontinuation LAM therapy occur occasionally , may lead liver-related morbidity mortality well premature interruption delay chemotherapy . Considering LAM therapy show relatively high rate drug resistance withdrawal hepatitis , study better choice prophylactic antiviral regimen warrant . The purpose study conduct multicenter , prospective , randomize study compare effect entecavir ( ETV ) versus LAM prevention HBV reactivation HBsAg-positive patient hematologic oncologic malignancy undergo cytotoxic chemotherapy . A total one hundred eighty HBV carrier malignancy undergo chemotherapy randomly assign prophylactic therapy arm ETV LAM group . The primary endpoint study HBV reactivation rate antiviral therapy 6 month discontinuation prophylactic antiviral therapy . If prophylactic efficacy ETV superior LAM , ETV prefer prophylactic therapy HBsAg-positive cancer patient undergo chemotherapy .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>18 year older positive HBsAg least 6 month inactive active carrier HBV ALT level &lt; 2xULN , chronic hepatitis compensate cirrhosis ( ChildPugh class A ) malignant tumor : nonHodgkin 's lymphoma undergoing systemic chemotherapy ; solid tumor undergo chemotherapy ( include adjuvant/neoadjuvant chemotherapy concurrent chemoradiation therapy ) positive antiHCV antiHIV antibody decompensated cirrhosis hepatocellular carcinoma expect survival less 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>malignancy</keyword>
	<keyword>hepatitis B</keyword>
	<keyword>lamivudine</keyword>
	<keyword>entecavir</keyword>
	<keyword>prophylaxis</keyword>
</DOC>